Synaptica Ltd.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Synaptica Ltd.
Scottish life science cluster rides the translational medicine wave
Translational medicine, stem cell therapy, personalised medicine and open collaboration: all are key factors in steering drug research towards a more productive future. And all are being brought together on a burgeoning science campus near Edinburgh that aims to draw the attention of the biopharmaceutical industry and investors and facilitate the launch of a dozen innovative spin-out companies over the next few years.
Edinburgh BioQuarter to spin out first companies
The new Edinburgh BioQuarter initiative in Scotland will be launching its first two bioscience spin-out companies in the coming weeks, its commercial director Dr Michael Capaldi told Scrip. These are likely to be followed by a further two or three companies by the end of the year. The companies will span a range of bioscience areas, from therapeutics - including orphan drugs, to devices and diagnostics.
Faust Pharmaceuticals
Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.
Faust Pharmaceuticals
Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- COSTNEAR LIMITED
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice